AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25297614 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 g/d)
Number of subjects: 17
Study 22446172 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfotiamine (300 mg/day)
Number of subjects: 67
Study 22446172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 20158623 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle factors including diet eating habits
Number of subjects: 170
Study 20158623 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle factors including resting and sleeping habits
Number of subjects: 170
Study 20158623 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle factors including drug usage patterns
Number of subjects: 170
Study 20158623 — intervention group
Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 170
Study 20158623 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 170
Study 20158623 — intervention group
Group type: COMPARATOR
Intervention: Stress levels
Number of subjects: 170
Study 18310585 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 0
Study 18310585 — intervention group
Group type: COMPARATOR
Intervention: Usual vocational rehabilitation
Number of subjects: 0
Study 18310585 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS service characteristics
Number of subjects: 0
Study 18310585 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient characteristics
Number of subjects: 0
Study 18310585 — intervention group
Group type: EXPERIMENTAL
Intervention: Service uptake
Number of subjects: 0
Study 15678299 — intervention group
Group type: EXPERIMENTAL
Intervention: Open kinetic chain (OKC) knee extensor resistance training
Number of subjects: 49
Study 15678299 — intervention group
Group type: COMPARATOR
Intervention: Closed kinetic chain (CKC) knee extensor resistance training
Number of subjects: 49
Study 11943441 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard spirometer (Renaissance spirometry system) with quality assurance program
Number of subjects: 2859
Study 10422925 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative autologous donation (3 U autologous blood)
Number of subjects: 79
Study 10422925 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO plus ANH (600 U/kg rHuEPO at 21 and 14 days before surgery and 300 U/kg on day of surgery followed by ANH)
Number of subjects: 79
Study 10422925 — intervention group
Group type: COMPARATOR
Intervention: ANH (blinded, placebo injections)
Number of subjects: 79
Study 10422925 — intervention group
Group type: COMPARATOR
Intervention: ANH
Number of subjects: 79
Study 7578656 — intervention group
Group type: EXPERIMENTAL
Intervention: All-night sleep EEG spectral analysis
Number of subjects: 0
Study 7578656 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonresponders)
Number of subjects: 0
Study 2104081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB) maintenance therapy (120 mg Bi2O3, one swallow tablet nocte)
Number of subjects: 71
Study 2104081 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 71
Study 692577 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution or uncoated tablets
Number of subjects: 6
Study 692577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release formulations (3 of 6)
Number of subjects: 6
Study 692577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release formulations (3)
Number of subjects: 6
Study 692577 — intervention group
Group type: COMPARATOR
Intervention: Uncoated tablets
Number of subjects: 6
Study 30917512 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatable comfort meal ingestion
Number of subjects: 24
Study 28427373 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help psycho-educational programme 'PERANTARA'
Number of subjects: 106
Study 25680689 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 3 grams daily for 3 weeks
Number of subjects: 8
Study 25680689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 23755929 — intervention group
Group type: EXPERIMENTAL
Intervention: ER tramadol 200 mg
Number of subjects: 24
Study 23755929 — intervention group
Group type: EXPERIMENTAL
Intervention: ER tramadol 600 mg
Number of subjects: 24
Study 23755929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20934556 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban high exposure (60 mg daily, adjusted for drug clearance)
Number of subjects: 20500
Study 20934556 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban low exposure (30 mg daily, adjusted for drug clearance)
Number of subjects: 20500
Study 20934556 — intervention group
Group type: COMPARATOR
Intervention: Warfarin titrated to an international normalized ratio of 2.0 to 3.0
Number of subjects: 20500
Study 20934556 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (both high and low exposure)
Number of subjects: 20500
Study 18574393 — intervention group
Group type: EXPERIMENTAL
Intervention: CBEP + PL
Number of subjects: 315
Study 18574393 — intervention group
Group type: COMPARATOR
Intervention: CBEP
Number of subjects: 315
Study 16630367 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Monitor (AM)
Number of subjects: 11
Study 14602878 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio-frequency catheter ablation of accessory pathways
Number of subjects: 224
Study 14602878 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 224
Study 10964871 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 8
Study 10964871 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 8
Study 10964871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1616967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg twice daily for 7 days)
Number of subjects: 119
Study 1616967 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (400 mg twice daily for 7 days)
Number of subjects: 119
Study 6369642 — intervention group
Group type: EXPERIMENTAL
Intervention: One-holed cannula
Number of subjects: 3066
Study 6369642 — intervention group
Group type: COMPARATOR
Intervention: Two-holed cannula (flexible and rigid)
Number of subjects: 3066
Study 6369642 — intervention group
Group type: COMPARATOR
Intervention: Three other cannulae groups (not specified)
Number of subjects: 3066
Study 31256104 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable standing desktop accessory
Number of subjects: 35
Study 31256104 — intervention group
Group type: COMPARATOR
Intervention: Standard work desk
Number of subjects: 35
Study 30208601 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 98
Study 30208601 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (Ca-antagonists)
Number of subjects: 98
Study 30208601 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACE-I)
Number of subjects: 98
Study 30208601 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 98
Study 27028279 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control (leaflets only)
Number of subjects: 5963
Study 27028279 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control (single session of advice)
Number of subjects: 5963
Study 27028279 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control (more than one session of advice)
Number of subjects: 5963
Study 27028279 — intervention group
Group type: COMPARATOR
Intervention: Increasing intensity of intervention by moving up a category
Number of subjects: 5963
Study 27028279 — intervention group
Group type: COMPARATOR
Intervention: Each additional weigh-in
Number of subjects: 5963
Study 23981048 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted yoga
Number of subjects: 46
Study 23981048 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study 22828694 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic thoracic facet joint nerve blocks
Number of subjects: 13
Study 22828694 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiofrequency neurotomy
Number of subjects: 13
Study 22828694 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic intraarticular injections
Number of subjects: 13
Study 22828694 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial branch blocks
Number of subjects: 13
Study 20499372 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 12
Study 20499372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18076259 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT(‐50%DeltaT) recovery
Number of subjects: 10
Study 18076259 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT and IVT(‐50%DeltaT)
Number of subjects: 10
Study 18076259 — intervention group
Group type: EXPERIMENTAL
Intervention: V(.‐)O2max values at IAT, IVT(+50%DeltaT), and IVT
Number of subjects: 10
Study 18076259 — intervention group
Group type: EXPERIMENTAL
Intervention: V(r) at IVT(‐50%DeltaT)
Number of subjects: 10
Study 16164814 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Directions-Small Business (HD-SB)
Number of subjects: 3959
Study 16164814 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Directions-Health Centers (HD-HC)
Number of subjects: 3959
Study 12011609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (n = 13)
Number of subjects: 48
Study 12011609 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (n = 13)
Number of subjects: 48
Study 12011609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 48
Study 12011609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 48
Study 12011609 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 48
Study 12011609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10449104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenercept (10, 50, or 100 mg IV every 4 weeks for up to 48 weeks)
Number of subjects: 168
Study 10449104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IV every 4 weeks for up to 48 weeks)
Number of subjects: 168
Study 8960851 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril (2.5‐5.0 mg/day)
Number of subjects: 105
Study 8960851 — intervention group
Group type: COMPARATOR
Intervention: atenolol (50‐100 mg/day)
Number of subjects: 105
Study 1678580 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 12
Study 1678580 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 12
Study 6297516 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (6g t.d.s. with meals)
Number of subjects: 19
Study 30600136 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0
Study 30600136 — intervention group
Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 0
Study 30600136 — intervention group
Group type: COMPARATOR
Intervention: lixisenatide
Number of subjects: 0
Study 27669447 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + SIT
Number of subjects: 71
Study 27669447 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + HIITHI
Number of subjects: 71
Study 27669447 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + PER
Number of subjects: 71
Study 27669447 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (all groups)
Number of subjects: 71
Study 27858881 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF plus PRF (group B)
Number of subjects: 56
Study 27858881 — intervention group
Group type: COMPARATOR
Intervention: CRF only (group A)
Number of subjects: 56
Study 24576401 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, high-carbohydrate (HFHC) meal
Number of subjects: 6
Study 24576401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lipid-tolerance test meal
Number of subjects: 6
Study 24576401 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy breakfast
Number of subjects: 6
Study 24576401 — intervention group
Group type: EXPERIMENTAL
Intervention: All meals
Number of subjects: 6
Study 22753560 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight control (BWC) program combined with activity-based peer intervention
Number of subjects: 118
Study 22753560 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight control (BWC) program combined with aerobic exercise
Number of subjects: 118
Study 22753560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BWC conditions
Number of subjects: 118
Study 20122250 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant radiotherapy (40 Gy)
Number of subjects: 1
Study 17986164 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS over M1 (2 mA, 20 minutes for five consecutive days)
Number of subjects: 32
Study 17986164 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS over DLPFC (2 mA, 20 minutes for five consecutive days)
Number of subjects: 32
Study 17986164 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study 16009004 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 545
Study 16009004 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive treatment
Number of subjects: 545
Study 11960154 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.6 mg/kg/day in 4 divided doses for first 4 days)
Number of subjects: 40
Study 11960154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11960154 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 40
Study 9707026 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet 90 mg/kg every 12 h for 15 days
Number of subjects: 39
Study 9707026 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir 5 mg/kg every 12 h for 15 days
Number of subjects: 39
Study 7631132 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR 400 micrograms.kg-1 plus DEC 6 mg.kg-1
Number of subjects: 57
Study 7631132 — intervention group
Group type: COMPARATOR
Intervention: DEC 6 mg.kg-1
Number of subjects: 57
Study 7631132 — intervention group
Group type: COMPARATOR
Intervention: IVR 400 micrograms.kg-1
Number of subjects: 57
Study 1947955 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan
Number of subjects: 39
Study 1947955 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 39
Study 6119685 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg daily
Number of subjects: 25
Study 31713733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F (TwHF) 40-60 mg/day
Number of subjects: 76
Study 31713733 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) 100 mg/day
Number of subjects: 76
Study 29856176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine with morphine plus nalbuphine (Group 2)
Number of subjects: 80
Study 29856176 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine with morphine (Group 1)
Number of subjects: 80
Study 29856176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 28859947 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 25982
Study 28859947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25982
Study 26507175 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-delivered smoking cessation intervention
Number of subjects: 200
Study 26507175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study 24168638 — intervention group
Group type: EXPERIMENTAL
Intervention: Online personal activity monitor (Gruve Solution™)
Number of subjects: 33
Study 24168638 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal daily activities)
Number of subjects: 33
Study 20596858 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 15
Study 18855089 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-mm metal-on-polyethylene bearing
Number of subjects: 0
Study 18855089 — intervention group
Group type: COMPARATOR
Intervention: 28-mm metal-on-metal bearing
Number of subjects: 0
Study 18855089 — intervention group
Group type: COMPARATOR
Intervention: 36-mm metal-on-metal bearing
Number of subjects: 0
Study 17709060 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (50 min, twice weekly for 4 weeks)
Number of subjects: 54
Study 17709060 — intervention group
Group type: COMPARATOR
Intervention: Guided relaxation (50 min, twice weekly for 4 weeks)
Number of subjects: 54
Study 17709060 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 54
Study 17709060 — intervention group
Group type: COMPARATOR
Intervention: Guided relaxation
Number of subjects: 54
Study 15468748 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based survey
Number of subjects: 7000
Study 15468748 — intervention group
Group type: COMPARATOR
Intervention: U.S. mail survey
Number of subjects: 7000
Study 11597532 — intervention group
Group type: EXPERIMENTAL
Intervention: BTA stat test
Number of subjects: 81
Study 11597532 — intervention group
Group type: COMPARATOR
Intervention: Voided Urine Cytology (VUC)
Number of subjects: 81
Study 11597532 — intervention group
Group type: COMPARATOR
Intervention: Ureteral Washing Cytology (UWC)
Number of subjects: 81
Study 9687407 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 50 mg
Number of subjects: 48
Study 9687407 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 100 mg
Number of subjects: 48
Study 9687407 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 200 mg
Number of subjects: 48
Study 9687407 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 48
Study 9687407 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 600 mg
Number of subjects: 48
Study 9687407 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 800 mg
Number of subjects: 48
Study 9687407 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 48
Study 8021578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 8021578 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 33
Study 8021578 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensive subjects
Number of subjects: 33
Study 8021578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 33
Study 2686488 — intervention group
Group type: COMPARATOR
Intervention: Control group (group K) - saline solution
Number of subjects: 140
Study 2686488 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg fentanyl (group 0,1F)
Number of subjects: 140
Study 2686488 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg fentanyl (group 0,2F)
Number of subjects: 140
Study 2686488 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg fentanyl (group 0,3F)
Number of subjects: 140
Study 2686488 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg nifedipine (group 1,0N)
Number of subjects: 140
Study 2686488 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg nifedipine + 0.1 mg fentanyl (group 0,5N + 0,1F)
Number of subjects: 140
Study 2686488 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg nifedipine + 0.1 mg fentanyl (group 1,0N + 0,1F)
Number of subjects: 140
Study 326638 — intervention group
Group type: EXPERIMENTAL
Intervention: Metiamide (400 mg)
Number of subjects: 16
Study 326638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31632735 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNTA)
Number of subjects: 8
Study 31632735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 28339403 — intervention group
Group type: EXPERIMENTAL
Intervention: DaTSCAN (immediate imaging upon diagnosis)
Number of subjects: 20
Study 28339403 — intervention group
Group type: COMPARATOR
Intervention: DaTSCAN (delayed imaging at 6 months)
Number of subjects: 20
Study 28339403 — intervention group
Group type: EXPERIMENTAL
Intervention: DaTSCAN (both groups)
Number of subjects: 20
Study 25464260 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term antihypertensive treatment (median follow-up of 20 days)
Number of subjects: 3056
Study 25464260 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quartile of PWV
Number of subjects: 3056
Study 25464260 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors related to smaller BP decline
Number of subjects: 3056
Study 23325372 — intervention group
Group type: EXPERIMENTAL
Intervention: aripiprazole + escitalopram
Number of subjects: 35
Study 23325372 — intervention group
Group type: COMPARATOR
Intervention: escitalopram
Number of subjects: 35
Study 21728080 — intervention group
Group type: EXPERIMENTAL
Intervention: AirWay Scope (AWS)
Number of subjects: 68
Study 21728080 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 68
Study 21728080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AWS and Macintosh laryngoscope
Number of subjects: 68
Study 19126368 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection
Number of subjects: 0
Study 19126368 — intervention group
Group type: COMPARATOR
Intervention: No epidural steroid injection (Control)
Number of subjects: 0
Study 17955651 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus acupoint-injection
Number of subjects: 78
Study 17955651 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture alone
Number of subjects: 78
Study 16020985 — intervention group
Group type: EXPERIMENTAL
Intervention: oral administration of trimetazidine, prednisolone, and vitamin B complex
Number of subjects: 108
Study 16020985 — intervention group
Group type: EXPERIMENTAL
Intervention: trimetazidine alone
Number of subjects: 108
Study 16020985 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone and vitamin B complex
Number of subjects: 108
Study 16020985 — intervention group
Group type: EXPERIMENTAL
Intervention: intravenous piracetam and prednisolone
Number of subjects: 108
Study 16020985 — intervention group
Group type: EXPERIMENTAL
Intervention: further treatment with trimetazidine for a month
Number of subjects: 108